Status:

COMPLETED

Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects

Lead Sponsor:

Nanomix

Conditions:

Covid19

Eligibility:

All Genders

18+ years

Brief Summary

Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Male or Female
  • Willing and able to provide informed consent
  • Symptomatic or asymptomatic
  • The EUA RT-PCR sample must be collected within one (1) day of the sample collected for testing by the Nanomix eLab® COVID-19 Rapid Antigen Panel.

Exclusion

  • Subjects without both a valid EUA RT-PCR test result and a valid Nanomix eLab® COVID-19 Rapid Antigen results will be excluded
  • Subjects not being able to provide consent

Key Trial Info

Start Date :

December 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 14 2021

Estimated Enrollment :

137 Patients enrolled

Trial Details

Trial ID

NCT04667442

Start Date

December 1 2020

End Date

December 14 2021

Last Update

December 27 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nanomix

Emeryville, California, United States, 94608